Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040183 · ClinicalTrials.gov registry record · Phase 3
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
A Phase 3 study of Pancreatic Cancer, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
- 20
- Study locations
NCT00040183: Completed Phase 3 study of Pancreatic Cancer, sponsored by OSI Pharmaceuticals.
NCT00040183 is a Phase 3 study of Pancreatic Cancer that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 569 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040183, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
Conditions Studied
Interventions
- DRUG Tarceva (erlotinib HCl, OSI-774)
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- Loma Linda University Cancer Institute - Loma Linda
- Metropolitan Hematology/Oncology Medical Group, Inc. - Los Angeles
- UCLA Medical Center - Los Angeles
- Kaiser Permanente - San Diego
Connecticut
- DeQuattro Community Cancer Center - Manchester
- New Britain General Hospital - New Britain
- Eastern Connecticut Oncology - Norwich
- Carl and Dorothy Bennett Cancer Center - Stamford
Florida
- Florida Cancer Specialists - Fort Myers
- Oncology Hematology Group of South Florida - Miami
- Ocala Oncology - Ocala
- Tampa General Hospital - Tampa
Illinois
- Onc/Hem Associates of Central Illinois - Peoria
- Hematology Oncology Associates of Illinois - Skokie
- Carle Cancer Center - Urbana
Arizona
- Arizona Clinical Research Center - Tucson
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Atlanta Cancer Center - Atlanta
Iowa
- University of Iowa Hospital & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2001-11-29 |
| Est. Completion | 2004-01-15 |
| Phase | Phase 3 |
What the finished NCT00040183 record still lists
NCT00040183 is an interventional study that assigns participants to a tested intervention. The registered 569 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarceva (erlotinib HCl, OSI-774) is the first listed.
NCT00040183 names 20 study sites across 8 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00040183 about?
NCT00040183 is a clinical study titled "OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.". The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
What is the current status of trial NCT00040183?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2001-11-29. Estimated completion is 2004-01-15.
What conditions does trial NCT00040183 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00040183?
The interventions under investigation include: Tarceva (erlotinib HCl, OSI-774) (DRUG).
Who is sponsoring clinical trial NCT00040183?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040183 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00040183's enrollment target sits among peer trials
569 25th of 278 higher than 253 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
- NCT07266831 · 570 participants · Phase 2
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI